Tremfya pharmaceutical market projected to reach 7.84 billion USD by 2035

SDKI Analytics has released a market research report forecasting the Tremfya pharmaceutical market. The market is projected to grow from approximately 3.23 billion USD in 2025 to roughly 7.84 billion USD by 2035, representing a compound annual growth rate (CAGR) of about 9.3% between 2026 and 2035.

Growth is driven by the expansion of IL-23 targeted therapies and a shift toward biological agents for treating immune-mediated diseases due to their long-term safety and efficacy. The expansion of indications to include inflammatory bowel diseases, such as ulcerative colitis and Crohn’s disease, is expected to significantly increase commercial potential beyond existing uses in psoriasis and psoriatic arthritis.

North America is predicted to maintain the largest market share, reaching approximately 42.0% by 2035, supported by high biological agent utilization, specialist networks, and robust reimbursement systems. However, challenges remain, including high treatment costs, strict medical reimbursement reviews, and competition from other biological agents in dermatology and gastroenterology.